Skip to main
  1. Stocks
  2. MannKind
  3. Forecast
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is attractive because its core commercial engines are showing durable demand and meaningful operating leverage, even if 3Q/26 revenue of $101.9MM missed estimates due to timing-related issues rather than weakening fundamentals. FUROSCIX is transitioning rapidly to ReadyFlow, with ~75% of shipments converted by late October and management expecting 90%+ of scripts in Q4, while Afrezza’s pediatric launch has already lifted TRx ~17% q/q and more than doubled pediatric prescriptions. Tyvaso DPI royalties added $37.5MM in 3Q/26, CVR overhang has been removed, and management expects Q4/26 profitability and annual profitability in 2027 without needing to raise capital.

Bears say

MannKind is viewed negatively because its valuation depends heavily on Tyvaso DPI royalties and collaboration revenue that could be pressured if UTHR launches a competing SMI treprostinil device in 2027, while the company has limited control over partner execution. Commercial diversification also looks fragile: Afrezza’s pediatric launch is early, FUROSCIX still has a short sales history, and 2026E revenue sits below management’s $110M–$120M target, suggesting slower-than-expected uptake could limit growth. Cost discipline is deteriorating as SG&A rose 111% year over year to $61.4MM versus estimates, R&D fell to $14.4MM due to study discontinuations, and adjusted net income was a $3.6MM loss, underscoring execution and pipeline risk.

MannKind (MNKD) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

MannKind (MNKD) Analyst Forecast & Price Prediction

Get the latest MannKind (MNKD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MannKind (MNKD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 8 analysts, MannKind (MNKD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


MannKind (MNKD) Analyst Forecast & Price Prediction

Get the latest MannKind (MNKD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MannKind (MNKD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MNKD stock data and trends